Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Bertoli

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
Leukemia & Lymphoma|June 9, 2020
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL studySuzanne Tavitian, Madalina Uzunov, Emilie Bérard, et al.
Blood Cancer Journal|January 6, 2022
Genomic landscape of hyperleukocytic acute myeloid leukemiaLaetitia Largeaud, Sarah Bertoli, Emilie Bérard, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Science Signaling|September 15, 2016
CHK1 as a therapeutic target to bypass chemoresistance in AMLLaure David, Anne Fernandez-Vidal, Sarah Bertoli, et al.
European Journal of Haematology|October 17, 2018
Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemiaSarah Bertoli, Etienne Paubelle, Emilie Bérard, et al.
Blood|February 1, 2013
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemiaSarah Bertoli, Emilie Bérard, Françoise Huguet, et al.
British Journal of Haematology|July 4, 2023
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational studyMaya Belhadj, Barbara Burroni, Olivier Kosmider, et al.
Oncotarget|November 15, 2011
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experienceOlivier LaRochelle, Sarah Bertoli, François Vergez, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
Leukemia & Lymphoma|June 9, 2020
Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL studySuzanne Tavitian, Madalina Uzunov, Emilie Bérard, et al.
Blood Cancer Journal|January 6, 2022
Genomic landscape of hyperleukocytic acute myeloid leukemiaLaetitia Largeaud, Sarah Bertoli, Emilie Bérard, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Science Signaling|September 15, 2016
CHK1 as a therapeutic target to bypass chemoresistance in AMLLaure David, Anne Fernandez-Vidal, Sarah Bertoli, et al.
European Journal of Haematology|October 17, 2018
Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemiaSarah Bertoli, Etienne Paubelle, Emilie Bérard, et al.
Blood|February 1, 2013
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemiaSarah Bertoli, Emilie Bérard, Françoise Huguet, et al.
British Journal of Haematology|July 4, 2023
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational studyMaya Belhadj, Barbara Burroni, Olivier Kosmider, et al.
Oncotarget|November 15, 2011
Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experienceOlivier LaRochelle, Sarah Bertoli, François Vergez, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Pageof 10